Mast cell activation syndrome and anesthesia
No society guideline exists. The plan is built from the pharmacology of histamine release and the individual patient’s trigger list — and the second one is more specific than the first.
Every clinical claim on this page is cited to its source below. How we source clinical content — including the corrections we have made and why.
Mast cell activation syndrome is one of the conditions where a patient often knows considerably more about their own triggers than the literature does. There is no society guideline for its perioperative management, and the practical plan is built from the pharmacology of mast cell degranulation plus the individual patient’s history.
Key takeaways
- The core principle is avoiding histamine-releasing agents where MCAS is present, and it is the one thing the perioperative literature consistently states.
- Continue the patient’s antihistamine regimen through the perioperative period rather than stopping it because they are fasting.
- Induction agents producing minimal hemodynamic change — etomidate or ketamine — have been suggested as preferable where dysautonomia coexists.
- Fentanyl, sufentanil and ketamine are described as good analgesic choices for maintaining hemodynamic stability without releasing histamine.
- MCAS is not anaphylaxis, but a degranulation event can look identical intraoperatively — and is treated the same way when it does.
- MCAS travels with hypermobile EDS and POTS. A patient with one frequently has the others.
The agents that matter
Mast cell degranulation can be triggered by direct pharmacologic histamine release, independent of any IgE-mediated allergy. That distinction is what makes the drug list matter: an agent can be entirely safe from an allergy standpoint and still be a poor choice here.
| Class | Consideration |
|---|---|
| Neuromuscular blockers | Historically the most-cited direct histamine releasers, with benzylisoquinolinium agents such as atracurium and mivacurium the classic examples. Rocuronium, vecuronium and cisatracurium are conventionally regarded as low-releasing |
| Opioids | Morphine and meperidine are the classic direct releasers. Fentanyl and sufentanil are described as good choices for maintaining stability without histamine release1 |
| Induction agents | Agents producing minimal hemodynamic change such as etomidate or ketamine may be preferred where dysautonomia coexists1 |
| Vancomycin | Rate-dependent direct release. Infuse slowly; the reaction is not an allergy and is dose-rate driven |
| NSAIDs | A recognized trigger in some patients; ask specifically rather than assuming tolerance |
| Contrast media, latex, chlorhexidine | Non-drug exposures worth checking, since they are frequently overlooked in a drug-focused history |
| Physical triggers | Temperature change, mechanical pressure and friction are described triggers, which makes positioning, warming and skin preparation part of the plan rather than incidental |
The most useful list is the patient’s own. MCAS triggers are highly individual, and most patients with an established diagnosis maintain a list of agents they have and have not tolerated. That list is more specific than any general table — including this one — and it should be obtained and read rather than summarized.
Building the plan
Preoperatively
- Continue the antihistamine regimen. H1 and H2 blockers taken chronically should be continued through the perioperative period rather than held for fasting.1
- Establish what a reaction looks like in this patient. Flushing, hypotension, bronchospasm, GI symptoms, urticaria — the presenting pattern is individual and knowing it in advance shortens recognition time.
- Ask about mastocytosis specifically. Systemic mastocytosis is a distinct clonal disorder with a higher risk profile than MCAS and warrants hematology input.
- Ask about co-diagnoses. Hypermobile EDS and POTS co-occur commonly, and each adds separate considerations.
- Premedication protocols vary. Regimens combining H1 and H2 blockade with a corticosteroid are widely used and institutionally variable; there is no consensus dose or timing.
Intraoperatively
- Choose agents deliberately using the table above and the patient’s list.
- Minimize the number of drugs. Every additional agent is another possible trigger and another confounder if a reaction occurs.
- Attend to physical triggers — temperature swings, prep solutions, adhesive and mechanical pressure.
- Have the anaphylaxis drugs immediately available, not merely in the building. Epinephrine is the treatment for a severe degranulation event as it is for anaphylaxis.
If a reaction occurs
Treat it as anaphylaxis. The distinction between IgE-mediated anaphylaxis and non-immunologic mast cell degranulation matters for the subsequent workup and for future anesthetics — it does not change the immediate management. Send a tryptase level: timing matters, and a baseline afterward allows the acute value to be interpreted.
One thing that separates MCAS from an allergy history. A patient who reacted to an agent may not have an IgE-mediated allergy to it, which means allergy testing can come back negative while the clinical event was entirely real. A negative test does not license rechallenge with a known direct histamine releaser in a patient who reacted to it.
What the evidence base actually is
Thin, and worth saying plainly. The perioperative recommendations here derive from reviews of coexisting conditions in connective tissue disorder populations1 and from the general pharmacology of histamine release, not from trials in MCAS patients. There is no randomized evidence, no society guideline, and considerable practice variation.
The practical consequence is that individual history carries unusual weight — previous anesthetic records, the patient’s own trigger list, and what has been tolerated before are the best available data.
Frequently asked questions
What anesthesia drugs are safe with MCAS?
There is no definitive safe list, but the general principle is to avoid agents that directly release histamine. Fentanyl, sufentanil and ketamine are described as good choices for maintaining hemodynamic stability without histamine release,1 and induction agents producing minimal hemodynamic change such as etomidate or ketamine may be preferred where dysautonomia coexists.1 The patient’s own record of what they have tolerated is more useful than any general list.
Which anesthetic drugs release histamine?
Classically, morphine and meperidine among opioids, and benzylisoquinolinium neuromuscular blockers such as atracurium and mivacurium. Vancomycin causes rate-dependent release that is not an allergy. NSAIDs, contrast media, latex and chlorhexidine are recognized triggers in some patients. Physical triggers including temperature change and mechanical pressure also matter.
Should I take my antihistamines before surgery?
Generally yes. Continuing the antihistamine regimen through the perioperative period is reasonable and is what the available perioperative guidance suggests1 — but confirm with your anesthesia team in advance, since fasting instructions frequently sweep up medications that should be continued.
Is MCAS the same as anaphylaxis?
No. Anaphylaxis is typically IgE-mediated; MCAS involves inappropriate mast cell degranulation that can be triggered directly by drugs and physical stimuli without an allergic mechanism. But a severe degranulation event can look identical intraoperatively and is treated identically — epinephrine first. The distinction matters for the subsequent workup, not the immediate response.
Can I have surgery safely with MCAS?
Yes, with planning. The elements are a deliberate agent selection, continuation of the antihistamine regimen, attention to physical triggers, and immediate availability of anaphylaxis treatment. The main limitation is that the evidence base consists of reviews and pharmacologic reasoning rather than trials, which makes the individual history unusually important.
Is MCAS related to Ehlers-Danlos syndrome and POTS?
They co-occur frequently, and a patient with one often has the others. Where all three are present, each contributes separate perioperative considerations — mast cell triggers and agent selection from MCAS, volume dependence and orthostatic intolerance from POTS, and joint and skin fragility plus local anesthetic resistance from hypermobile EDS.
References
- Perioperative care in patients with Ehlers-Danlos syndromes. Review covering coexisting mast cell activation syndrome, dysautonomia and gastroparesis. Sources the recommendations to avoid histamine-releasing agents, to prefer induction agents with minimal hemodynamic change such as etomidate or ketamine, and to use fentanyl, sufentanil or ketamine for analgesia without histamine release.
- Further reading. Laserna A, Nishtar M, Vidovich C, Borovcanin Z. Perioperative management of Ehlers-Danlos type III syndrome associated with postural orthostatic tachycardia in patients undergoing general anesthesia. Cureus. 2021;13(11):e19311. doi:10.7759/cureus.19311
- Further reading. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. Context for the co-occurring conditions.
Disclaimer. Reference information for licensed clinicians and students. Not a medical device, and not a substitute for clinical judgment. There is no society guideline for the perioperative management of mast cell activation syndrome; the guidance here derives from reviews and pharmacologic reasoning rather than trials in this population. Verify against your institutional protocol and current package inserts.
Agent selection and trigger avoidance like this ship inside Helix Anesthesia — a point-of-care reference built by a practicing CRNA, cited and available offline. See how we source clinical content.
Helix Anesthesia is a reference tool for the people looking after you rather than something you need yourself — but the sourcing behind every number in it is public, and you are welcome to read it.
How we source clinical contentHypermobility and dysautonomia
- Ehlers-Danlos syndrome — start here
- POTS
Preparing for surgery yourself? What to tell your anesthesia provider — the plain-language version. · All clinical answers